Journal
AMERICAN JOURNAL OF CARDIOLOGY
Volume 109, Issue 3, Pages 307-313Publisher
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjcard.2011.09.014
Keywords
-
Categories
Funding
- British Heart Foundation, London, United Kingdom
- National Institute for Health Research, London, United Kingdom
- Myocardial Ischemia National Audit Project
Ask authors/readers for more resources
Risk assessment is central to the management of acute coronary syndromes. Often, however, assessment is not complete until the troponin concentration is available. Using 2 multicenter prospective observational studies (Evaluation of Methods and Management of Acute Coronary Events [EMMACE] 2, test cohort, 1,843 patients; and EMMACE-1, validation cohort, 550 patients) of unselected patients with acute coronary syndromes, a point-of-admission risk stratification tool using frontal QRS-T angle derived from automated measurements and age for the prediction of 30-day and 2-year mortality was evaluated. Two-year mortality was lowest in patients with frontal QRS-T angles <38 degrees and highest in patients with frontal QRS-T angles >104 degrees (44.7% vs 14.8%, p <0.001). Increasing frontal QRS-T angle age risk (FAAR) scores were associated with increasing 30-day and 2-year mortality (for 2-year mortality, score 0 = 3.7%, score 4 = 57%; p <0.001). The FAAR score was a good discriminator of mortality (C statistics 0.74 [95% confidence interval 0.71 to 0.781 at 30 days and 0.77 [95% confidence interval 0.75 to 0.791 at 2 years), maintained its performance in the EMMACE-1 cohort at 30 days (C statistics 0.76 (95% confidence interval 0.71 to 0.81 at 30 days and 0.79(95% confidence interval 0.75 to 0.831 at 2 years), in men and women, in ST-segment elevation myocardial infarction and non ST-segment elevation myocardial infarction, and compared favorably with the Global Registry of Acute Coronary Events (GRACE) score. The integrated discrimination improvement (age to FAAR score at 30 days and at 2 years in EMMACE-1 and EMMACE-2) was p <0.001. In conclusion, the FAAR score is a point-of-admission risk tool that predicts 30-day and 2-year mortality from 2 variables across a spectrum of patients with acute coronary syndromes. It does not require the results of biomarker assays or rely on the subjective interpretation of electrocardiograms. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;109:307-313)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available